Updated hourlyHourly refreshWed, Oct 28, 2026
Finance · Healthcare
Financial Highlights
For the six months Ended 30 June 2026
(HK$ million)
2026
2025
Change
Revenue
2,071.0
2,014.2
+2.8%
Gross Profit
731.0
677.0
+8.0%
Gross Profit margin
35.3%
33.6%
+1.7pp
Profit attributable to owners of the Company
175.2
157.0
+11.6%
Net profit margin
8.5%
7.8%
+0.7pp
Adjusted EBITDA
330.8
303.2
+9.1%
Earnings per share (HK cents)
16.79
15.05
+11.6%
HONG KONG, August 25, 2026 - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) has announced its interim results for the six months ended 30 June 2026 (“the reporting period”).
During the reporting period, the Group delivered solid profit growth, primarily driven by the resilient performance of its instant noodle business. Revenue increased by 2.8% year-on-year from HK$2,014.2 million in 2025 to HK$2,071.0 million in 2026, reflecting continued momentum in its core instant noodle business and broader store coverage in the Chinese Mainland. Gross profit increased by 8.0% year-on-year from HK$677.0 million to HK$731.0 million. Gross profit margin improved by 1.7 percentage points from 33.6% year-on-year to 35.3%, driven primarily by the continued expansion of the higher-margin core instant noodle business, the effective execution of raw material procurement strategies which helped mitigate the impact of raw material price volatility, and improved production efficiency.
Profit attributable to owners of the Company increased by 11.6% from HK$157.0 million in 2025 to HK$175.2 million in 2026, representing a net profit margin of 8.5% for the period. The Group’s basic earnings per share increased from 15.05 HK cents to 16.79 HK cents for the period. Adjusted EBITDA increased by 9.1% from HK$303.2 million to HK$330.8 million, representing the Adjusted EBITDA margin of 16.0% for the period, reflecting improved profitability at the operating level.
Review and Prospects of Different Business Regions
During the reporting period, revenue from the Hong Kong and other regions operations remained stable, increasing by 0.2% to HK$793.5 million (2025: HK$792.3 million), mainly attributable to the continued steady performance of the instant noodle business in the Hong Kong market and increased demand in other regions. Revenue from Chinese Mainland operations increased by 4.5% (in local currency: -0.1%) to HK$1,277.5 million (2025: HK$1,221.9 million), mainly attributable to the increased sales volume of instant noodles and the positive impact of foreign currency translation.
In Hong Kong, the instant noodles business delivered steady growth, driven by the resilient performance of flagship brands including Demae Iccho, Hokkaido Iccho, Cup Noodles and Cup Noodles BIG. To further enrich its instant noodle portfolio, the Group introduced a range of new SKUs, such as Nissin Stir Cup Noodles Seafood Flavour Instant Noodle and Nissin Viet Signature Beef Flavour Pho Noodle, and Demae Iccho Scallop and Salt Soup Flavour Instant Noodle. Continuing its IP promotion strategy, the collaboration with Japanese virtual singer “Hatsune Miku” also enhanced brand awareness and strengthened engagement with younger consumers.
As for non-noodle business, the Group expanded its premium frozen food portfolio with the launch of the “Doll Dim Sum” series. The Group also introduced a series of limited-edition products to capture seasonal demand and drive sales. Meanwhile, health-focused products, including the Hong Kong-made Nissin Granola and fresh-cut vegetable, continued to gain popularity, reflecting the Company’s commitment to health and wellness. In May 2026, the Group entered into a strategic partnership with Itochu Hong Kong Limited through a joint investment in Nissin Marketing and Sales (H.K.) Limited, which is expected to support the long-term development and competitiveness of the distribution business in Hong Kong and the Chinese Mainland.
In other regions, the Company continued to strengthen its presence in Vietnam with a focus on the youth segment to support instant noodles brand growth and market penetration. In Korea, Gaemi Food’s business performance was stable during the period, with the strategic focus on the expansion of its e-commerce business, enhancement of consumer engagement through “KEMY Mall”, and continuous product innovation. Gaemi Food continued to expand its presence in overseas markets including Hong Kong, Vietnam, and Taiwan. In Australia, ABC Pastry recorded stable performance supported by the launch of a range of new premium products. Australia Nissin also maintained solid business momentum during the period, driven by increased sales of instant noodles across nationwide supermarket chains and Asian supermarket channels through ongoing market development efforts and product innovation.
In the Chinese Mainland, the Group continued to advance its premiumisation strategy and strengthen its business foundation, while increasing instant noodle sales volume through broader market coverage and more diversified distribution channels. It upgraded select Cup Noodles products by increasing ingredient sizes to deliver an improved tasting experience for consumers. To further enrich its product line-up, the Company also introduced new products such as Nissin U.F.O. Singapore Chilli Crab Flavour, reinforcing its premium and innovative brand positioning. The Company continued its collaboration with the Japanese virtual singer "Hatsune Miku" to raise brand awareness and strengthen connections with consumers. As for the non-noodle business, the Company continued to strengthen its snacks, beverage and frozen food businesses through product innovation to address evolving consumer demand.
Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite continuing market volatility and geopolitical uncertainties, the Group delivered solid profit growth in the first half of 2026. This was supported by broader market coverage and the resulting increase in sales volume of our flagship brands. These results reflect the resilience of our business model and the effectiveness of our strategic initiatives. Our premiumisation strategy, diversified product portfolio and disciplined cost management have further strengthened our capability to navigate changing market conditions. As we continue to expand our presence in Hong Kong, the Chinese Mainland and overseas markets, we remain focused on delivering quality products and strengthening our brands. We are committed to achieving sustainable long-term growth and creating value for our shareholders.”
About Nissin Foods Company Limited
Nissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL (公仔)” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.
Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk.
Aug 25 · 04:45·ACN Newswire
Healthcare · Cybersecurity
National class action firm offering free case evaluations to individuals impacted by the Surgeons Choice Medical Center cybersecurity incident SOUTHFIELD, Mich., Aug. 24, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims...
Aug 25 · 02:29·PR Newswire
Finance · Healthcare
NANJING, China, Aug. 24, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile.
Aug 25 · 02:25·GlobeNewswire
Finance · Healthcare
THE WOODLANDS, TX, Aug. 24, 2026 -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.
Aug 25 · 01:06·GlobeNewswire
Healthcare · Biotech & pharma
SHANGHAI and HONG KONG, Aug. 24, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Aug 25 · 00:30·PR Newswire
Healthcare
Vancouver, British Columbia--(August 24, 2026) - Apptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement of up to 8,000,000 units of the Company (the "Units"), at a price of $0.125 per Unit, for aggregate gross proceeds of up to $1,000,000 (the "Offering"). The Company reserves the right to increase the size of the Offering in its sole discretion. The Offering is not subject to a...
Aug 25 · 00:00·Newsfile
Healthcare · Biotech & pharma
- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 -- Astellas Pharma Inc. (TSE: 4503,...
Aug 24 · 23:30·PR Newswire
Healthcare · Biotech & pharma
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood...
Aug 24 · 23:12·PR Newswire
Healthcare · Biotech & pharma
NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICESVancouver, British Columbia--(August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta...
Aug 24 · 22:42·Newsfile
Healthcare · Energy
Toronto, Ontario--(August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500...
Aug 24 · 21:01·Newsfile
Finance · AI
Vancouver, British Columbia, Aug. 24, 2026 -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”) announces that it has granted an aggregate 24,000 stock options, exercisable at $0.70 per share and valid for a term of three years, and an aggregate 276,053 restricted share units, valid for a term between one to three years, to consultants of the Company and its subsidiary. The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and 96,000 restricted share units and all stock options are subject to vesting over one year. All securities are subject to a hold period of four months and one day in accordance with applicable securities laws and policies of the Canadian Securities Exchange.
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 750,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact:
www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI
essam.hamza@rocketdoctor.ai
Dr. Bill Cherniak, CEO, Rocket Doctor Inc.
bill@rocketdoctor.io
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the granting of stock options and restricted share units to consultants, the terms and vesting conditions of such stock options and restricted share units, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include the risk that the stock options or restricted share units may not vest on the anticipated terms, risks related to the Company’s share compensation plan, and other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
Aug 24 · 21:00·GlobeNewswire
Finance · Healthcare
VAUGHAN, Ontario, August 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.
Aug 24 · 20:30·Business Wire